|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003320,
umls-concept:C0036849,
umls-concept:C0039194,
umls-concept:C0042214,
umls-concept:C0085358,
umls-concept:C0599894,
umls-concept:C0871261,
umls-concept:C1332714,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1442518,
umls-concept:C1521840,
umls-concept:C1552652,
umls-concept:C1552685,
umls-concept:C1704632,
umls-concept:C1705195,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C2698600,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-5-21
|
|
pubmed:abstractText |
Recent studies have defined vaccinia virus (VACV)-specific CD8(+) T cell epitopes in mice and humans. However, little is known about the epitope specificities of CD4(+) T cell responses. In this study, we identified 14 I-A(b)-restricted VACV-specific CD4(+) T cell epitopes by screening a large set of 2146 different 15-mer peptides in C57BL/6 mice. These epitopes account for approximately 20% of the total anti-VACV CD4(+) T cell response and are derived from 13 different viral proteins. Surprisingly, none of the CD4(+) T cell epitopes identified was derived from VACV virulence factors. Although early Ags were recognized, late Ags predominated as CD4(+) T cell targets. These results are in contrast to what was previously found in CD8(+) T cells responses, where early Ags, including virulence factors, were prominently recognized. Taken together, these results highlight fundamental differences in immunodominance of CD4(+) and CD8(+) T cell responses to a complex pathogen.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
pubmed-author:BuiHuynh-HoaHH,
pubmed-author:CroftMichaelM,
pubmed-author:CrottyShaneS,
pubmed-author:GreyHowardH,
pubmed-author:LefkowitzElliot JEJ,
pubmed-author:MoutaftsiMagdaliniM,
pubmed-author:OseroffCarlaC,
pubmed-author:PasquettoValerieV,
pubmed-author:PetersBjoernB,
pubmed-author:Salek-ArdakaniShahramS,
pubmed-author:SetteAlessandroA,
pubmed-author:SidneyJohnJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
178
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6814-20
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17513729-Amino Acid Sequence,
pubmed-meshheading:17513729-Animals,
pubmed-meshheading:17513729-Antigens, Viral,
pubmed-meshheading:17513729-CD4-Positive T-Lymphocytes,
pubmed-meshheading:17513729-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17513729-Epitopes, T-Lymphocyte,
pubmed-meshheading:17513729-H-2 Antigens,
pubmed-meshheading:17513729-Histocompatibility Antigens Class II,
pubmed-meshheading:17513729-Immunodominant Epitopes,
pubmed-meshheading:17513729-Mice,
pubmed-meshheading:17513729-Mice, Inbred C57BL,
pubmed-meshheading:17513729-Molecular Sequence Data,
pubmed-meshheading:17513729-Protein Binding,
pubmed-meshheading:17513729-Vaccinia,
pubmed-meshheading:17513729-Vaccinia virus
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses.
|
|
pubmed:affiliation |
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
